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PTEN L/L prostate luminal epithelial cells can form tumors which are 
insensitive to inhibition of EIF4E activity in vivo. Representative 
immunofluorescence images of the anterior (AP), dorsal (DP), and 
ventral (VP) prostate in PTEN L/L prostate cancer mice with and without 
induction of the 4EBP1M transgene which inhibits eIF4E activity in a 
tissue specific manner in vivo. Basal epithelial cells (green, CK5+) are 
sensitive to inhibition of eIF4E activity, while luminal epithelial cells (red, 
CK8+) are resistant. 
 





Whole-genome sequencing of various cancers has heralded a new era of targeted therapies and 
provides the tantalizing prospect of personalized medicine. These sequencing studies revealed that 
the PI3K-AKT-mTOR pathway is commonly altered in cancer and thus major efforts have been 
devoted to develop and test PI3K-AKT-mTOR inhibitors. Most, if not all, advanced prostate cancers 
harbor alterations in this pathway. While PI3K-AKT-mTOR pathway inhibitors have shown promise in 
preclinical studies, drug resistance often develops. However, it remains unknown if all types of 
epithelial cells present in normal or cancerous prostate glands are equally sensitive to such 
inhibitors. A new Fred Hutch study led by Dr. Andrew Hsieh (Human Biology and Clinical Research 
Divisions) leveraged a combination of a new prostate cancer mouse model, a clinical trial and 
detailed molecular studies to reveal that the protein synthesis inhibitor 4EBP1 is critically involved in 
prostate cancer initiation, progression and drug resistance. This study was recently published in the 
journal Science Signaling. 
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The study began with an intriguing observation from a previous preclinical trial of an ATP-site mTOR 
inhibitor (MLN0128) in mice that develop prostate cancer due to prostate-specific deletion of the 
tumor suppressor PTEN (PTEN
L/L
 mice). The prostate gland is composed of two distinct epithelial 
cell types: luminal cells (CK8
+
) and basal cells (CK5
+
). Dr. Hsieh and his collaborators at UCSF 
observed tumors that resisted an 8-week course of treatment with MLN0128 were enriched in CK8
+
 
luminal cells, relative to CK5
+
 basal cells. To determine the molecular basis for this differential 
sensitivity to mTOR inhibitors, the authors queried the protein abundance of key components of the 
protein synthesis machinery, including eIF4A, eIF4E, eIF4G and 4EBP1. Western blotting of 
fluorescence activated cell sorting (FACS)-sorted basal or luminal cells obtained from PTEN
L/L
 mice 
showed that 4EBP1, an inhibitor of cap-dependent translation, was the only component of this 
machinery analyzed found to be enriched in both in normal and PTEN
L/L
 luminal cells compared to 
basal cells. Importantly, this increased 4EBP1 expression was likely functional as luminal cells 
exhibited the lowest rates or protein synthesis, as demonstrated by 
35
S methionine incorporation 
assays on FACS-sorted cells. 
Because 4EBP1 functions primarily by inhibiting the mTOR-regulated oncogene eIF4E, the authors 
sought to determine the role of 4EBP1 in vivo. To this end, they developed a novel genetic mouse 
model, wherein a doxycycline-inducible expression of a mTOR-insensitive mutant (4EBP1M) was 
combined with the PTEN
L/L
 model. Said Dr. Hsieh: "Historically it has been difficult to inhibit protein 
synthesis in a tissue specific inducible manner. We overcame this hurdle by developing a new 
prostate cancer mouse model called the PTEN
L/L
; 4EBP1M mouse. Here, PTEN loss leads to 
prostate cancer, and the addition of doxycycline to the drinking water induces a transgene, which 
can inhibit protein synthesis in vivo. Using this model we demonstrate that eIF4E mediated 
translation is essential for prostate cancer initiation and progression." Expression of 4EBP1M 
markedly decreased both the development and maintenance of prostate cancer, concomitant with an 
increase in apoptosis. Strikingly, 4EBP1M expression led to an enrichment of luminal cells, 
suggesting basal cells, but not luminal cells, require eIF4E for growth and survival. These findings 
along with in vitro molecular studies provide a mechanistic rationale for why tumor prone luminal 
epithelial cells are uniquely resistant to PI3K pathway inhibitors. 
Finally, the authors sought to determine whether increased 4EBP1 abundance also occurs in 
prostate cancer patients. Comparison of pre-treatment with post-treatment prostate cancer tissue 
from an ongoing clinical trial with a PI3K inhibitor (BKM120) revealed an enrichment of CK8
+
 luminal 
cells that expressed high levels of 4EBP1. In conclusion, this study showed that cell type-specific 
expression of the tumor suppressor 4EBP1 in luminal prostate cancer cells primes cells for either 
sensitivity or resistance to PI3K-AKT-mTOR inhibitors and may have utility in predicting drug 
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responses in patients. "Our laboratory has discovered that protein synthesis rates of specific 
prostate epithelial cell types can tune them for resistance to an emerging line of PI3K pathway 
inhibitors," said Hsieh. Reflecting on the meaning of these findings, Hsieh said, "Many questions 
remain. If low protein synthesis leads to drug resistance, will more potent inhibitors of protein 
synthesis lead to drug sensitivity? What are the downstream translationally regulated transcripts that 
direct the therapeutic response and drug resistance?" 
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